Market News AIOpen the app

Craig-Hallum has started following Quoin Pharmaceuticals and thinks its shares are a good buy at $16.

OpinionRead the original at moomoo.com
Good for QNRX

Craig-Hallum gave QNRX a Buy rating and a $16 share target, a favorable outside view. The report gives no new trial or sales results, so the support comes from the analyst's opinion alone.

QNRX · Quoin Pharmaceuticals

AI read · Good for QNRX

The AI's read

A favorable rating can draw attention to Quoin and shows that Craig-Hallum sees promise in its shares. The story reports no new trial result or sales change, so this is an outside opinion, not proof of business progress.

Get alerts for QNRX

Follow Quoin Pharmaceuticals (QNRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for QNRX
Free on the App Store and Google Play, or on the web.